GlassScriptPhysician profile
Jay A Lugthart
NPI 1215059241
$7,022.51
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,298 · 2020: $700 · 2021: $1,358 · 2022: $1,729 · 2023: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $936.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,481.89 | 2019-2023 | Farxiga, Breztri |
| Novo Nordisk INC | $918.86 | 2019-2023 | Wegovy, Saxenda |
| Lilly USA, LLC | $442.58 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Amgen INC. | $433.67 | 2019-2023 | Otezla, Repatha, Prolia |
| Glaxosmithkline, LLC. | $416.96 | 2019-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $401.15 | 2019-2022 | |
| Abbvie INC. | $376.73 | 2021-2023 | |
| Amarin Pharma, INC. | $248.52 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $211.97 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.39 | 2019-2023 | Stiolto Respimat |
| Merck Sharp & Dohme LLC | $133.73 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.61 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $117.98 | 2019-2023 | Austedo Xr, Ajovy |
| Biohaven Pharmaceuticals, INC. | $83.65 | 2021 | |
| Sanofi-Aventis U.S. LLC | $73.74 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $43.99 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $42.36 | 2022-2023 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $39.97 | 2019 | |
| Eisai INC. | $38.14 | 2021 | |
| Nabriva Therapeutics, Plc | $31.54 | 2021-2022 | |
| Exact Sciences Corporation | $26.07 | 2023 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $25.92 | 2021 | |
| Promius Pharma LLC | $24.73 | 2019 | |
| Pfizer INC. | $23.36 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $21.39 | 2023 | Gvoke Hypopen |
| Astellas Pharma US INC | $18.63 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.55 | 2022 | |
| Allergan, INC. | $14.90 | 2020 | |
| Esperion Therapeutics, INC. | $13.19 | 2021 | |
| Antares Pharma, INC. | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Lugthart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.